Non-Invasive Ventilation in Emergencies: How to Apply NIV Correctly

Non-invasive ventilation (NIV) is one of the most effective interventions for acute respiratory failure – and at the same time one of those measures that in clinical practice is frequently applied too late, with incorrect settings, or in unsuitable patients. When applied correctly, NIV reduces intubation rates, shortens ICU stays, and significantly reduces mortality in selected conditions. When applied incorrectly, it delays a necessary intubation and worsens outcomes. This article provides you with a practical overview of indications, contraindications, device settings, monitoring, and clear criteria for discontinuation – so you can make well-informed decisions in an emergency.

Pathophysiological Principles: Why NIV Works

To use NIV effectively, it's worth taking a brief look at the underlying physiology. Acute respiratory failure can be simplified into two types:

• Type 1 (hypoxemic): Oxygenation failure with normal or decreased pCO₂. Typical causes: alveolar pulmonary edema, pneumonia, ARDS.
• Type 2 (hypercapnic): Ventilation failure with elevated pCO₂ and respiratory acidosis. Typical causes: COPD exacerbation, neuromuscular exhaustion.

NIV works through two key mechanisms:

1. Positive end-expiratory pressure (PEEP/EPAP): Keeps alveoli open, recruits atelectatic lung regions, reduces intrapulmonary shunt, and improves oxygenation. In cardiogenic pulmonary edema, the increase in intrathoracic pressure additionally reduces left ventricular preload and afterload – a therapeutically desired hemodynamic effect.
2. Inspiratory pressure support (IPAP/PS): Reduces the work of breathing, unloads the exhausted respiratory muscles, and improves tidal volume – crucial in hypercapnic failure.

Understanding these mechanisms determines whether you choose CPAP or BiPAP and what pressures you set.

Indications: When to Use NIV?

The evidence for NIV is not equally strong across all forms of respiratory failure. The two main indications with the best supporting data are:

COPD Exacerbation with Respiratory Acidosis

This is the indication with the strongest evidence. NIV demonstrably reduces intubation rates, mortality, and length of stay. The criteria for NIV use are:

• pH < 7.35 with pCO₂ > 45 mmHg despite optimized pharmacological therapy (bronchodilators, steroids, oxygen)
• Clinical signs of respiratory exhaustion: tachypnea > 24/min, use of accessory respiratory muscles, paradoxical breathing
• Preserved consciousness and cooperative patient

Important: A pH of 7.25–7.35 marks the "sweet spot" for NIV in COPD. At pH < 7.25, the risk of NIV failure increases significantly – you should still attempt NIV here, but you must have a very low threshold for intubation.

Acute Cardiogenic Pulmonary Edema

In cardiogenic pulmonary edema, NIV is a first-line therapy alongside nitrates and diuretics. The primary mechanisms here are:

• Preload reduction through increased intrathoracic pressure
• Improvement of oxygenation through alveolar recruitment
• Reduction of left ventricular afterload

Both CPAP and BiPAP are effective in this indication. The data show a significant reduction in intubation rates and improvement in clinical parameters within the first hour.

Additional Indications

With less robust evidence, but clinically justifiable:

• Immunocompromised patients with acute hypoxemic insufficiency (NIV as a bridge to avoid the risks of invasive ventilation)
• Post-extubation failure in high-risk patients
• Palliative setting: NIV for symptom relief of dyspnea when intubation is not desired
• Chest trauma with flail chest and impaired respiratory mechanics
• Asthma exacerbation: The evidence is weaker here, and you should maintain a very low threshold for escalation

When to Use NIV in Hypoxemic Insufficiency Without Pulmonary Edema?

In de novo hypoxemic failure (e.g., community-acquired pneumonia, ARDS), the data are significantly more critical. Studies show that NIV often only delays intubation without improving outcomes – with the risk that patients are in worse condition by the time intubation becomes necessary. In this situation, high-flow nasal cannula (HFNC) deserves particular attention as an alternative.

Contraindications: When Not to Use NIV

Absolute contraindications are clearly defined and must be verified before every NIV attempt:

• Respiratory arrest / agonal breathing → immediate intubation
• Unconsciousness (GCS < 8) without a rapidly reversible cause → aspiration risk
• Absent protective reflexes → no secure airway
• Hemodynamic instability (shock index > 1, refractory hypotension) → intubation under controlled conditions
• Facial trauma / facial surgery → mask cannot be fitted
• Upper gastrointestinal bleeding or active vomiting → aspiration risk
• Undrained pneumothorax

Relative contraindications requiring careful risk-benefit assessment:

• Excessive secretion burden that the patient cannot clear by coughing
• Severe agitation or claustrophobia
• Recent esophageal or gastric surgery
• Severe hypoxemia with SpO₂ < 85% despite maximum FiO₂

CPAP vs. BiPAP: Choosing the Right Modality

The choice between CPAP and BiPAP is not a matter of preference but is guided by the underlying pathophysiology.

CPAP (Continuous Positive Airway Pressure)

• Delivers one constant pressure during both inspiration and expiration
• Works primarily through alveolar recruitment and PEEP effect
• Main indication: Cardiogenic pulmonary edema, purely hypoxemic insufficiency
• Advantage: Simple to use, also available prehospitally with single-use systems (e.g., Boussignac CPAP)
• Starting settings: CPAP 5–10 cmH₂O, titrate FiO₂ to SpO₂ target

BiPAP (Bilevel Positive Airway Pressure)

• Delivers two pressure levels: IPAP (inspiratory) and EPAP (expiratory)
• The difference IPAP – EPAP = pressure support, which unloads the respiratory muscles and improves ventilation
• Main indication: Hypercapnic failure (COPD exacerbation), mixed insufficiency
• Starting settings:
  • EPAP: 4–6 cmH₂O
  • IPAP: 10–14 cmH₂O (pressure support at least 5–6 cmH₂O above EPAP)
  • FiO₂: Titrate to SpO₂ 88–92% in COPD, 92–96% in other pathologies
  • Backup respiratory rate: 12–16/min

Practical Tip for Pressure Titration

Start with moderate pressures and titrate upward in 2 cmH₂O increments every 5–10 minutes until:

• Respiratory rate decreases (< 25/min)
• Use of accessory respiratory muscles diminishes
• SpO₂ is within the target range
• The patient reports subjective relief

Maximum pressures: IPAP should generally not exceed 20–24 cmH₂O (gastric insufflation, leakage, patient comfort). If these pressures are insufficient, this is a warning sign of NIV failure.

Mask Selection and Interface

The best device settings are of little use if the mask doesn't fit. Mask selection is an underestimated success factor:

• Oronasal mask (full-face): Standard interface in emergencies. Covers mouth and nose, prevents leakage during mouth breathing. Disadvantage: aspiration risk during vomiting, claustrophobia.
• Nasal mask: Better tolerated, but ineffective in emergencies when the patient breathes through the mouth.
• Total face mask (helmet): Very well tolerated, lower risk of pressure injuries. However, requires higher pressures and specialized equipment.

Practical tips:

• Hold the mask in place with your hand initially before securing the straps – this gives the patient a sense of control and reduces anxiety
• The mask should fit snugly but not too tightly: you should be able to fit two fingers under the straps
• Nasal pressure injuries develop quickly – check the skin regularly and use hydrocolloid dressings prophylactically

Monitoring During NIV: What You Need to Watch

NIV is not a "set-and-forget" therapy. Close monitoring during the first 30–60 minutes determines success or discontinuation.

Clinical Parameters (continuous)

• Respiratory rate: Should decrease within 30 minutes. Persistent tachypnea > 30–35/min is a warning sign
• Respiratory effort: Use of accessory muscles, nasal flaring, paradoxical abdominal breathing
• Level of consciousness: Increasing somnolence under NIV is an alarm sign
• Patient comfort: Agitation, restlessness, mask tolerance
• Hemodynamics: Blood pressure, heart rate – high pressures can critically reduce preload

Device-Based Monitoring

• SpO₂: Continuous, target value depending on pathology
• Arterial blood gas analysis (ABG): Critical! First ABG after 30–60 minutes of NIV. Improvement in pH and pCO₂ = best predictor of NIV success
• Tidal volume: If readable on the device – excessive tidal volumes (> 9–10 mL/kg IBW) in hypoxemic insufficiency are associated with poor outcomes (so-called Patient Self-Inflicted Lung Injury, P-SILI)
• Leakage: Modern devices display leakage – ideally < 25 L/min

Criteria for Discontinuation: When NIV Fails

The most difficult aspect of NIV is the decision to discontinue. Waiting too long in NIV failure demonstrably worsens patient outcomes. The following criteria indicate NIV failure and the need for intubation:

Early Failure (< 1 hour)

• No improvement or deterioration of respiratory rate
• Persistent or worsening hypoxemia (SpO₂ < 88% despite FiO₂ > 0.6)
• Increasing agitation or decreasing level of consciousness
• Hemodynamic instability
• Mask intolerance despite optimized fitting and mild sedation

Late Failure (1–48 hours)

• No improvement in pH on ABG after 1–2 hours
• pCO₂ continues to rise or remains unchanged despite optimized pressures
• Increasing patient exhaustion
• New organ failure

Specific ABG Criteria for NIV Failure in COPD

• pH still < 7.25 after 1 hour of NIV → high failure rate, consider intubation
• pH < 7.30 after 1 hour of NIV with no trend toward improvement → intensified monitoring, intubation readiness
• pH ≥ 7.30 after 1 hour of NIV with improving trend → continue NIV, next ABG in 2–4 hours

Remember: Define the time point for reevaluation at the start of NIV. Communicate with your team: "We are initiating an NIV trial now. ABG check in 30 minutes. If the pH doesn't improve, we intubate." This proactive planning prevents the dangerous inertia of "let's just wait a bit longer."

Sedation During NIV

Mild sedation can improve mask tolerance but must be dosed very carefully, as respiratory depression accelerates NIV failure:

• Dexmedetomidine: Agent of choice in the ICU setting. Minimal respiratory depression, good anxiolytic effect. Dosing: 0.2–0.7 µg/kg/h as continuous infusion.
• Morphine: In low doses (1–2 mg IV titrated) in cardiogenic pulmonary edema to reduce the sympathoadrenal stress response and dyspnea. Caution: respiratory depression.
• Benzodiazepines: Generally avoid in emergency NIV – high risk of respiratory depression and paradoxical agitation.

Common Mistakes in Practice

We regularly see the following mistakes in practice – and they are avoidable:

1. Starting too late: NIV in COPD exacerbation initiated only after hours in the resuscitation bay instead of upon arrival. The earlier NIV is started, the better the outcome.
2. Pressures too low: IPAP of 8 cmH₂O above EPAP of 4 cmH₂O delivers a pressure support of only 4 cmH₂O – this is usually insufficient in the acute setting.
3. Wrong modality: CPAP in a hypercapnic COPD patient without inspiratory pressure support does not adequately improve ventilation.
4. No clear discontinuation point: NIV is continued for hours despite no clinical improvement – intubation then occurs under significantly worse conditions.
5. Missing ABG follow-up: Without an ABG after 30–60 minutes, there is no objective basis for decision-making.
6. Neglecting baseline therapy: NIV does not replace bronchodilators, steroids, nitrates, or diuretics – it is an add-on.

Summary: NIV Algorithm in Emergencies

1. Check indication: COPD exacerbation with pH < 7.35? Cardiogenic pulmonary edema? → NIV indicated
2. Rule out contraindications: Consciousness? Protective reflexes? Hemodynamics?
3. Choose modality: Hypercapnia → BiPAP. Pure oxygenation problem → CPAP (or BiPAP)
4. Apply interface: Oronasal mask, initially hold in place by hand, reassure the patient
5. Starting pressures: EPAP 5 cmH₂O, IPAP 10–12 cmH₂O, FiO₂ as needed
6. Titrate: Every 5–10 minutes by 2 cmH₂O based on clinical response
7. ABG after 30–60 minutes: pH improved? pCO₂ decreasing? → Continue. No improvement? → Intubation readiness
8. Close monitoring: Respiratory rate, SpO₂, level of consciousness, hemodynamics
9. Adhere to discontinuation criteria: A planned early intubation is always preferable to a late emergency intubation

Practical Training

Non-invasive ventilation in emergencies is a measure that must work under time pressure, with uncooperative patients, and with complex decision pathways. Device settings, mask selection, pressure titration, and the critical decision between continuing NIV and intubation are best practiced in realistic simulation scenarios. In our emergency training courses at Simulation Tirol, you practice exactly these situations hands-on – from initial setup through troubleshooting leakage to structured reevaluation. More information is available at simulation.tirol/kurse/notfalltraining.